Clin2
NCT06931990Possibly a fitRecruiting

Testing a new tablet for eczema in Chinese adults

Atopic Dermatitis (AD)

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
24 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are 18 to 75 years old
  • Your eczema has not improved enough with prescription creams or you cannot use them
  • You have used moisturizer daily for at least a week before starting the study
  • You do not have other skin conditions that could affect the results, like psoriasis or lupus
  • You are willing to use effective birth control during the study and for 6 months after the last dose

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07784816Not yet recruiting· Phase 2/Phase 3
TLL-018 for moderate-to-severe atopic dermatitis

This study tests an investigational medicine called TLL-018 (taken by mouth) for people with moderate-to-severe atopic dermatitis (also known as eczema). The goal is to see if it reduces symptoms like itching and skin patches, and to check for safety and side effects.

Beijing
NCT07235384Recruiting· Phase 1
Zai Lab tests ZL-1503 for moderate to severe eczema

This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.

Woolloongabba, Queensland
NCT07465120Not yet recruiting· Phase 2
Testing CMS-D001 for moderate to severe eczema

This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.

Beijing, Beijing Municipality
NCT07399067Recruiting· Phase 2
Testing IBI3002 for moderate to severe eczema

This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.

Beijing, Beijing Municipality
NCT07193589Recruiting· Phase 2
Testing ZL-82 tablets for moderate to severe eczema

This study tests if an oral tablet called ZL-82 can help people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to other treatments. It aims to find a new option for controlling this chronic skin condition.

Chengdu, Sichuan
NCT06723080Recruiting· Phase 3
Oral VC005 for moderate to severe eczema

This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.

Nanjing, Jiangsu

Hear when a new Atopic Dermatitis (AD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.